Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma
NCT00687765
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
126
Enrollment
INDUSTRY
Sponsor class
Conditions
Glioblastoma
Interventions
DRUG:
bsi-201 plus temozolomide
Sponsor
Sanofi